Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525274 | 0.77 | GRIN2D (0.36) | HSP90AA1 | |
| Hydrochloric Acid SCHEMBL9034672 | 0.73 | GRIN2D (0.34) | HSP90AA1 | |
| SCHEMBL367068 | 0.73 | — | — | |
| SCHEMBL3346816 | 0.72 | KMT2A (0.36) | HSP90AA1 | |
| SCHEMBL15254357 | 0.71 | HTT (0.32) | — | |
| SCHEMBL6434324 | 0.68 | APP (0.32) | — | |
| SCHEMBL3346811 | 0.67 | CPB2 (0.36) | HSP90AA1 | |
| SCHEMBL8727452 | 0.65 | HSP90AA1 (0.33) | HSP90AA1 | |
| SCHEMBL2629790 | 0.62 | HSP90AA1 (0.33) | HSP90AA1 | |
| SCHEMBL14600585 | 0.62 | HSP90AA1 (0.33) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101681107-B | Photosensitive resin composition, photosensitive element, method for forming resist pattern, and method for producing printed wiring board | HITACHI CHEMICAL CO LTD | 2012-12-26 | — | — | CN | disclosed |
| US-7709473-B2 | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors | PFIZER INC. (US) | 2010-05-04 | — | — | US | disclosed |
| CN-101681107-A | Photosensitive resin composition, photosensitive element, method for forming resist pattern, and method for producing printed wiring board | HITACHI CHEMICAL CO LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-10-25 | — | — | US | disclosed |
| EP-1678180-B1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1678180-A1 | SUBSTITUTED 2H- 1,2,4 TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1613629-A1 | SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES | Pfizer Products Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005035532-A1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2004085439-A1 | SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | HSP90AA1 3187/4885 |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | HSP90AA1 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.